A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding

作者：Douthwaite Julie; Moisan Jacques; Privezentzev Cyril; Soskic Blagoje; Sabbah Shereen; Cohen Suzanne; Collinson Andie; England Elizabeth; Huntington Catherine; Kemp Ben; Zhuang Li; Hudak Suzanne; Rees D Gareth; Goldberg Debbie; Barton Chris; Chang Linda; Vainshtein Inna; Liang Meina; Iciek Laurie; Ambery Philip; Peakman Mark; Vaughan Tristan J; Tree Tim I M; Sansom David M; Bowen Michael A; Minter Ralph R; Jermutus Lutz^*

来源：The Journal of Immunology, 2017, 198(1): 528-537.

DOI：10.4049/jimmunol.1600682

Affinity-and stability-engineered variants of CTLA4-Ig fusion molecules with enhanced pharmacokinetic profiles could yield improved therapies with the potential of higher efficacy and greater convenience to patients. In this study, to our knowledge, we have, for the first time, used in vitro evolution to simultaneously optimize CTLA4 affinity and stability. We selected for improved binding to both ligands, CD80 and CD86, and screened as dimeric Fc fusions directly in functional assays to identify variants with stronger suppression of in vitro T cell activation. The majority of CTLA4 molecules showing the largest potency gains in primary in vitro and ex vivo human cell assays, using PBMCs from type 1 diabetes patients, had significant improvements in CD80, but only modest gains in CD86 binding. We furthermore observed different potency rankings between our lead molecule MEDI5265, abatacept, and belatacept, depending on which type of APC was used, with MEDI5265 consistently being the most potent. We then created fusions of both stability-and potency-optimized CTLA4 moieties with human Fc variants conferring extended plasma t(1/2). In a cynomolgus model of T cell-dependent Ab response, the CTLA4-Ig variant MEDI5265 could be formulated at >100 mg/ml for s.c. administration and showed superior efficacy and significantly prolonged serum t(1/2). The combination of higher stability and potency with prolonged pharmacokinetics could be compatible with very infrequent, s.c. dosing while maintaining a similar level of immune suppression to more frequently and i.v. administered licensed therapies.

• 出版日期2017-1-1